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Analysis of Mammalian O-Glycopeptides—We
Have Made a Good Start, but There is a Long
Way to Go*□S
Zsuzsanna Darula‡ and Katalin F. Medzihradszky‡§¶
Glycosylation is perhaps the most common post-transla-
tional modification. Recently there has been growing in-
terest in cataloging the glycan structures, glycoproteins,
and specific sites modified and deciphering the biological
functions of glycosylation. Although the results are piling
up for N-glycosylation, O-glycosylation is seriously trail-
ing behind. In our review we reiterate the difficulties
researchers have to overcome in order to characterize
O-glycosylation. We describe how an ingenious cell en-
gineering method delivered exciting results, and what
could we gain from “wild-type” samples. Although we
refer to the biological role(s) of O-glycosylation, we do not
provide a complete inventory on this topic. Molecular &
Cellular Proteomics 17: 10.1074/mcp.MR117.000126, 2–
17, 2018.
To understand the biological role of glycosylation, in an
ideal world one would study intact glycoproteins. Recent
developments have made such analyses possible (1), but
proteins modified at multiple sites, displaying significant
macro- as well as microheterogeneity still represent a chal-
lenge. Mostly the chromatographic separation is lacking.
One would have to separate the protein of interest from all
other components, and somehow fractionate the isomeric
structures. Even with relatively successful top-down exper-
iments (1, 2), one also has to collect data using the “second
best” solutions (1) studying the glycan pool that provides
detailed information about the carbohydrate structures; (2)
characterizing intact glycopeptides that provide information
about the microheterogeneity; (3) gaining information about
the unmodified sequences that may yield information about
the macroheterogeneity.
The Different “Classes” of Extracellular O-Glycosylation
All O-glycopeptides feature a carbohydrate residue cova-
lently linked to the hydroxyl group of an amino acid. Among
the coded amino acids serine, threonine and tyrosine can be
modified this way. The modifying sugar unit directly linked to
the amino acid could be Fuc, Glc, GalNAc, GlcNAc, Man, and
Xyl. The modifications are performed in the ER1 and the Golgi.
Thus, they affect secreted proteins and the extracellular do-
main of membrane proteins. The lumenal side of ER, Golgi
and certain vesicles are considered as such.
O-Fucosylation—-linked O-fucose modification was orig-
inally considered EGF-domain specific (3). Its consensus se-
quence was determined as CXXGG(S/T)C and the observa-
tion of an elongated structure, NeuAc2,6Gal1,4GlcNAc1,
3Fuc has also been reported (Fig. 1A (4)). The presence of the
2 Gly residues N-terminal to the site of glycosylation is not a
very strict requirement. For example, Thr-3103 of Versican
core protein, preceded by an Ala instead of Gly, has been
detected bearing a single Fuc, as well as di- and trisaccha-
rides (5, 6). Thrombospondin type 1 repeats (TSRs) also may
be O-fucosylated (7, 8). Presently, the CX2/3(S/T)CX2G se-
quence is considered as the consensus motif (9). Both con-
sensus motifs are linked somewhat to the Cys-framework
within the specified domains, and the enzymes performing the
“deposition” of the core sugar unit are Protein O-fucosyl
transferase-1 and 2 for EGF or TSR domains, respectively
(8, 10). The glycan extension also follows two distinct path-
ways (11). Fucoses on the EGF domain can be elongated to
the above mentioned tetrasaccharide, whereas in TSRs only a
1,3-linked Glc is added to the core unit. Our knowledge
about the biological function(s) of O-fucosylation is quite lim-
ited, though it has been implicated in protein-protein interac-
tions, intercellular signaling and protein folding (9, 12, 13). The
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O-fucosylation of the IgG1 light chain has also been reported.
The modified sequence does not comply with any of the
consensus requirements listed above, and it features only the
-linked Fuc (14). This observation suggests the existence of
a different pathway.
O-Glucosylation—O-Glucosylation was first described on
blood clotting Factors VII and IX (15, 16). The -linked Glc
residue was reported to be elongated with one or two 
1,3-linked Xyl moieties (Fig. 1B (17)). The modification seems
to be EGF-domain-specific, Protein Z as well as thrombos-
pondin have been reported as modified in their EGF domains
(16, 18). Recently, both O-glucosylation and fucosylation has
been reported on the EGF-like domain of AMACO, an extra-
cellular matrix protein of unknown function (19). Already the
first reports speculated that there is a consensus motif for
O-glucosylation: CXSXPC (16). The enzyme responsible for
the modification is O-glucosyltransferase Rumi (20). Interest-
ingly, Rumi also may function as protein O-xylosyltransferase
(21). The exact biological role of this modification has not
been deciphered yet, but EGF-glucosylation seems to be
essential for mouse embryonic development and Notch sig-
naling (22).
O-GalNAcylation or Mucin-type Glycosylation—This is the
most common mammalian O-glycosylation. It was named
after a family of secreted and transmembrane proteins that
feature heavily glycosylated repetitive peptide stretches, the
so-called “variable number of tandem repeat” regions. More
than 20 different GalNAc-transferases may perform the pri-
mary glycosylation step (23). As these glycosyltransferases
display distinct but overlapping substrate specificities (24),
there is no consensus motif for mucin-type O-glycosylation,
although there are some tendencies. Thr residues are modi-
fied to much higher extent compared with Ser (25, 26). Pro,
and to lesser extent, Ser, Thr, Ala, and Gly residues are
overrepresented around modification sites (24–28). Eight dif-
ferent core structures exist (Fig. 2) (23). Core-1–4 structures
may be considered common, core-1 and core-2 (that may be
considered a branched core-1) glycans are the most fre-
quently occurring ones in serum (29). The core-1 structure is
the only type of glycan that has been identified on Tyr-resi-
dues unambiguously so far (30, 31). Cores 1 and 2 may be
elongated into poly-N-acetyllactosamine chains and may fea-
ture antigens, such as blood-type determinants (23, 32, 33).
Even some small O-linked structures are antigenic: the core
GalNAc by itself or sialylated in the sixth position as well as
the core-1 disaccharide, and these are termed as Tn, sialyl-Tn
and T antigens, respectively (23). Cores 5–8 are rare, and
have been detected only from specific sources (23). All cores
may be modified with sialic acids - terminal Gal residues bear
only 2,3-linked ones. Covalent modifications of these mucin-
type glycans have been reported, such as the O-acetylation of
neuraminic acid (1, 23, 34), and the sulfation of different Gal
and GlcNAc units (23, 35, 36). Mucin-type O-glycosylation
has been implicated in a wide variety of biological processes,
such as interaction with pathogens (37, 38), cell adhesion
(39–41), and proteolytic processing (40, 42–45). Altered gly-
cosylation patterns have been linked to different diseases. For
example, defective glycosylation of IgA1 has been reported in
patients with IgA nephropathy and Henoch-Schoenlein pur-
pura nephritis (46). It has also been documented that the
O-glycosylation pattern is altered by cancer (24): higher Tn
antigen levels increase its invasiveness (47, 48).
O-GlcNAcylation—It has been known for decades that Ser
and Thr residues of nuclear and cytosolic proteins may be
modified with a -linked GlcNAc (49). O-GlcNAcylation fulfills
signaling and regulatory functions within the cell (50). Both the
enzyme performing the glycosylation as well as the glycosi-
dase removing it have been identified (51–54). More recently,
it has been reported that extracellular proteins also may fea-
ture this modification (55). The enzyme performing the mod-
ification within the ER lumen, EGF-domain-specific O-linked
N-acetylglucosamine transferase has first been identified in
Drosophila (56) and later in mammals (57). In Drosophila this
modification has been implicated in cell-cell interaction (56).
The biological role(s) of extracellular O-GlcNAcylation in
mammals has not been determined yet, although multiple
proteins have been found bearing O-GlcNAc in extracellular
environment (5).
O-Mannosylation—O-mannosylation was originally catego-
rized as a unique fungal type of O-glycosylation. Later it was
discovered that mammalian dystroglycans also bear such
modifications (Fig. 3 (58)), and their glycosylation deficiency
leads to pathological changes (58). Cadherins were also iden-
tified as extensively modified with O-mannosyl glycans (59)
and that O-mannosylation of E-cadherin is crucial for cell
adhesion (60). The modification is initiated in the ER, and from
various studies only a handful of additional glycoproteins
were found O-mannosylated (6, 61–63). O-glycan studies re-
vealed that mammalian brain is especially rich in such modi-
fications (64). In this study, the existence of branched O-
mannosyl glycan structures was also demonstrated (64), the
core Man is modified with an additional, 1,6-linked GlcNAc
that may be further elongated (65). It has been reported that
branched O-mannosyl structures displaying HNK-1 epitopes
(sulfoglucuronyl “capping”) influence cell-cell and cell-matrix
interactions in the developing nervous system (66). Recently,
FIG. 1. Detailed structures of O-fucosyl glycan (A) (4); and O-
glucosyl glycan (B) (17).
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protein modification with a single mannose residue has also
been reported (67, 68).
O-Xylosylation—In a special class of glycoproteins, pro-
teoglycans the core saccharide unit is xylose and it modifies
Ser residues. Proteoglycans feature huge extended glycan
chains: glycosaminoglycans (GAGs). This type of O-glycosy-
lation will not be discussed in this paper, for an excellent
summary on the structure and biosynthesis of proteoglycans
see chapter 17 of (23).
Difficulties Encountered in O-Glycosylation Analysis
Despite the differences among the glycosylation processes,
the resulting glycans and their biological roles, the different
classes of O-glycosylation represent very similar analytical
challenges.
The Lack of Consensus Motif—Although N-glycosylation
features a consensus motif, and the potential sites can usually
be isolated in individual peptides upon proteolytic treatment,
the same is not true for O-glycopeptides. Because so many
different glycosyltransferases are involved in the primary pro-
tein modification, not surprisingly, there is no universal con-
sensus motif. Multiple potential modification sites are present
in most of the peptides irrespective of the proteolytic enzyme
used, and not infrequently these sites are clustered. Only
O-glucosylation and O-fucosylation are different, as these are
linked to specific domains, and the modified amino acids are
in a specific position in reference to the disulfide bridges (see
above).
However, as described earlier the existence of a fucosyl-
transferase of different specificity cannot be excluded (14).
Significant Macroheterogeneity—N-glycosites are believed
mostly highly, if not fully occupied—although because the
glycopeptides are usually selectively enriched the available
information may not be entirely reliable (69, 70). O-linked
glycosylation sites may feature a lot more significant macro-
heterogeneity - most available data seem to suggest this (25,
71). However, there are reports that indicate the full occu-
pancy of certain modification sites (72, 73). At the same time,
assessing the occupancy rates for O-glycopeptides even in a
single protein is extremely challenging because the ionization
efficiency of the unmodified and differently glycosylated se-
quences is not the same and cannot be calculated or pre-
dicted. Identification of lower abundance glycoforms is also
hampered by the chromatographic behavior of differently
modified glycopeptides (see later).
Microheterogeneity—Although N-linked glycosylation sites
may feature 50 different glycan structures (6), the glycan
repertoire of individual O-glycosylation sites seems to be
more limited (6, 74). At the same time, the O-glycan-pool
analyses of gastric mucins revealed an impressive array of
oligosaccharide structures (32, 33). However, this diversity
has not yet been “translated” to site-specific modifications.
Nevertheless, it has been reported that the same sites can be
FIG. 2. Mucin-type glycan core structures.
FIG. 3. The detailed structures of some O-mannosyl glycans
(58).
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modified by glycans of different mucin-type core structures
(75, 76), or mannosyl as well as GalNAc-core glycans (6, 77).
It has also been reported that the mucin-type core structure
may be altered during recycling (78). Assessing the macro-
and microheterogeneity is complicated by the presence of
multiple and (frequently) clustered modification sites whose
differential occupancy may yield numerous isomeric struc-
tures. Complexity is also increased by rampant proteolytic
digestion in body fluids (25, 79, 80).
Chromatographic Behavior—The vast majority of proteo-
mics data is acquired using reversed-phase separation of the
sample components before MS/MS analysis. Increasing acid-
ity leads to longer reversed phase retention times for N-
glycopeptides when weak acids, such as formic or acetic acid
are used as ion pairing agents, i.e. in most LC-MS/MS exper-
iments (34). The addition of a few “neutral” sugar units, for
example, an extra antenna, does not alter the retention times
significantly, and different N-glycoforms of the same acidity
usually coelute (6, 34, 81). Thus, from the accurately meas-
ured masses of the coeluting components additional glyco-
forms can be identified even if no MS/MS data were acquired
or relatively poor MS/MS spectra resulted from the analyses
(6). O-glycopeptides are somewhat different in this aspect.
Acidic O-glycopeptides also elute later than their neutral
counterparts (34). At the same time, the addition of just a
disaccharide at a different position, i.e. multiple modification
has an even more profound effect on their chromatographic
behavior. It has been documented that because of such al-
teration the retention time might be shortened by as much as
5 min when a relatively shallow LC gradient was applied (80).
Thus, finding all O-glycoforms represents a bigger challenge
even in single protein analysis than the characterization of
N-glycosylation.
MS/MS Behavior—Mass spectrometry has become the
method of choice for all kind of PTM analyses. It has been
essential for the characterization of glycosylation as well. Here
we present what information can be gleaned from spectra
acquired using different MS/MS techniques. All our examples
represent mucin-type glycosylation. However, the few exist-
ing/available data on the other type of O-glycopeptides indi-
cate that the rules of fragmentation are very similar for the
other cores as well (see references for Fuc (5, 6, 14); Glc (82);
Man (6, 83); and GlcNAc (84)).
Collision-induced dissociation is the most widely used
MS/MS activation method. It was reported more than two
decades ago that the favored process in the CID analysis of
O-glycosylation is the gas-phase loss of the glycan via a
rearrangement reaction without leaving a telltale sign on the
previously modified residue (85). Since then, numerous pa-
pers and reviews discussed the CID fragmentation pattern of
O-glycopeptides and also the possibility and limitations of
peptide sequence and modification site assignments (86, 87).
Fig. 4 represents the “typical” ion trap CID fragmentation of
an O-glycopeptide decorated with a simple oligosaccharide.
These data were acquired from a tryptic digest, in LC/MS/MS
mode on an LTQ-Orbitrap XL mass spectrometer (Thermo
Fisher Scientific, Waltham, MA). Although the precursor ions
were measured with high resolution, the CID acquisition was
performed in the linear ion trap. Ion trap CID is a resonance-
activation process leading mostly to single bond cleavages.
Glycosidic bond fragmentation clearly dominates the spec-
trum. Not surprisingly very abundant fragments were detected
with charge retention at the reducing end (more precisely on
the peptide connected to it). These are the so-called Y ions,
numbered from the reducing end of the glycan (for nomen-
clature see (88)). Such sugar-unit-loss ions may be formed
with the same charge as the precursor ion, but also at lower
charge states. The only clearly visible nonreducing end frag-
ments in this spectrum represent the terminal neuraminic acid
atm/z 292 and 274, i.e. the B1 fragment and an ion formed via
water loss from it, respectively. The B3 fragment (Neu-
AcHexHexNAc, at m/z 657) was also detected, however,
practically at the noise level. Among the fragments unac-
counted for there is one that seems to be present both as
singly and doubly charged (remember, the spectrum was
recorded with low resolution and low mass accuracy). One
could guess that it is most likely a peptide y fragment formed
in front of a Pro residue. O-glycopeptides frequently contain
prolines (27, 28), and this imino acid usually yields an abun-
dant y ion. In addition, the other half of the peptide, i.e. the
corresponding b fragment may also be unusually abundant.
This is the case for this peptide, the corresponding b ion was
indeed detected at m/z 1612 (yibn-i  MH
1), still bearing
the trisaccharide. Interestingly, this fragment was also de-
tected without the terminal sialic acid at m/z 1321 indicating
secondary fragmentation, unexpected in ion trap CID. To sum
it up, from these data one can deduce the composition of the
glycan: NeuAcHexHexNAc, the linearity of its structure, and
the mass of the peptide. One can speculate that it may be
about 17 residues long, and a Pro residue may be present
within the sequence, and the glycosylation occurs N-termi-
nally from this Pro. Measuring the fragments in the Orbitrap
would confirm the charge states guessed, and deliver masses
with high accuracy, but the amino acid sequence and the
modification site still would not be identified whereas some of
the weaker ions might be lost because of the lower sensitivity
of the analyzer.
Beam-type CID performed in collision cells (Q-TOF instru-
ments or HCD (higher-energy C-trap dissociation) in Thermo
mass spectrometers) may provide much needed information
on the identity of the peptide at the expense of the glycan
characterization. The beam-type CID spectrum of the same
glycopeptide (Fig. 5) is full of informative peptide fragments,
the modified sequence can readily be identified as AVGAQV-
LESTPPPHVMR [682–698] of Uniprot F1MNW4, bovine ITIH2
protein. However, one can only guess/calculate the glycan
mass and structure because of the (usually) complete loss of
the glycan structure upon this type of activation. The oxonium
Mammalian O-glycosylation
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ions clearly indicate the presence of neuraminic acid (m/z 274
and 292) and GalNAc (m/z 204). This latter fragment ion is
diagnostic for both GlcNAc and GalNAc, but the distribution
of further fragments clearly establishes GalNAc on this pep-
tide (89). One can then consider the simplest mucin-type
sialylated structure, NeuAcGalGalNAc and the presence of
the doubly charged Y0 at m/z 895.49(2) confirms our hunch.
(Because the ion trap CID data revealed the mass and linearity
of the glycan as well as the mass of the peptide, using ion trap
and beam-type CID data combined may deliver more reliable
and faster results. Except we do not know of any software that
enables one to perform O-glycopeptide analysis doing so.) A
database search will deliver the peptide identification once
the proper glycan structure is permitted as variable modifica-
tion. However, site assignments usually cannot be accom-
plished from CID/HCD data. In our example either Ser-10 or
Thr-11 bears the trisaccharide. Thus, the C-terminal frag-
ments starting from y8 or y9 should feature the appropriate
mass shift, except each was detected without the modifica-
tion, and that is rather typical for beam-type CID spectra.
Sometimes abundant peptide fragments (typically represent-
ing Xxx-Pro bond cleavages) may be observed both unmod-
ified and partially or fully retaining the glycan. One certainly
could try to lower the collision energy to prevent sugar losses.
Acquiring data at different collision energies may provide
sufficient information for both sequence identification and site
assignment. However, the extent of fragmentation depends
on a lot of factors, and finding the optimal conditions for most
components in automated LC/MS/MS settings may be a
daunting task.
Electron capture and electron transfer dissociation (ECD
and ETD, respectively), two recent MS/MS activation meth-
ods, lead to the formation of radical precursor ions that un-
dergo fragmentation mostly yielding peptide backbone frag-
ments via cleavages between the amino group and the alpha
carbon, while retaining the amino acid side chains and their
modifications intact (90, 91). Thus, efficient ECD/ETD frag-
mentation enables both the identification of the modified pep-
tide and the assignment of the site of modification. Indeed,
practically all recent successful O-glycosylation studies used
radical based fragmentation to decipher modification sites (6,
25, 26, 74, 79, 80, 92–95). ECD is performed in FT-ICR mass
spectrometers, whereas ETD works in ion traps and more
efficiently. Thus, we included an ETD spectrum to illustrate the
advantages and limitations of the method. Fig. 6 shows the
ETD spectrum of the human homologue of the earlier de-
scribed ITIH2 peptide. This spectrum was acquired from m/z
733.692(3) precursor ion, in the linear ion trap of an LTQ-
FIG. 4. Ion trap CID data of m/z 815.731(3). From these data one can deduce the composition of the glycan: NeuAcHexHexNAc, the
linearity of its structure, and the mass of the peptide. One can speculate that it may be about 17 residues long, and a Pro residue may be
present within the sequence, and the glycosylation occurs N-terminally from this Pro. The peptide fragment numbering in parantheses indicates
that the lengths of the corresponding sequence stretches were guessed from the m/z values.
Mammalian O-glycosylation
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Orbitrap Elite mass spectrometer (Thermo Fisher Scientific).
Because in ETD the amino acid side chains mostly remain
intact, one has to make assumptions about the glycans pres-
ent, and has to provide a list of variable modifications during
the database search. It is practical to start with the most
common structures or with the targeted glycans if a selective
enrichment was performed. In our case the human serum
sample was treated with neuraminidase, thus, only HexNAc
(representing GalNAc) and HexHexNAc (representing GalGal-
NAc) modifications were considered. From the spectrum pre-
sented AQGSQVLES(HexNAcHex)TPPPHVMR [682–698] of
Uniprot P19823, human ITIH2 protein was identified with high
confidence. However, the modification site assignment had to
be confirmed manually. Ser-4 could be excluded as modifi-
cation site by the presence of unmodified N-terminal fragment
ion series c4-c8. However, the other potential sites are in
adjacent positions, and the observation of c9 and/or z8 was
necessary to make an unambiguous site assignment. As in-
dicated with its red color, only z8 was detected, unmodified,
and thus, Ser-9 was assigned as the glycosylation site. Inter-
estingly, most of the C-terminal fragments were observed as
z1 ions, the products of hydrogen migration (96), and some
carbohydrate fragmentation, reported earlier for O-glycopep-
tides (92, 97) was also detected. The ETD fragments also
could have been measured in the Orbitrap, with high reso-
lution and mass accuracy making the assignments more
reliable, but unfortunately at the expense of sensitivity.
The Thermo Tribrid mass spectrometers (Thermo Fisher
Scientific), with new design features dramatically improved
the sensitivity of ETD analysis. Thus, measuring the fragments
in the Orbitrap analyzer does not translate into significant
information loss. In addition, a new MS/MS activation option,
EThcD has been made available. In this hybrid technique ETD
activation is performed first, then the entire “ion package” is
subjected to mild HCD activation to achieve higher sequence
coverage (98). Recently, EThcD has been promoted for the
more efficient analysis of post-translationally modified se-
quences, including glycopeptides (2). An EThcD spectrum is
presented in Fig. 7. These data were acquired on an Orbitrap
Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Sci-
entific) from a precursor ion at m/z 624.950(3) (with the
default NCE value of 15%), the fragments were measured at
high resolution and with high mass accuracy in the Orbitrap.
This activation combines the advantages of collision-in-
duced and radical-driven dissociation. First, we have plenty of
information on the modified amino acid sequence in form
FIG. 5. Beam-type (Q-TOF) CID data of m/z 815.73(3). From these data one could identify the modified peptide as AVGAQVLESTP-
PPHVMR ([682–698] of bovine ITIH2 protein (Uniprot ID: F1MNW4)). The glycan composition can be “guessed” from the oxonium ions of
HexNAc and Neu5Ac, and from the presence of m/z 895.49(2) as Neu5AcHexHexNAc. Intensity pattern of the fragments of the HexNAc
oxonium ion (m/z 204) ascertain its identity as GalNAc (89). Thus, the sugar structure is most likely Neu5AcGalGalNAc. Its linearity or branching
cannot be determined, because larger Y fragments were not detected, nor were m/z 454.16 or 495.18 observed, indicating sialylation of Gal
or GalNAc, respectively. The site of modification cannot be assigned. All ions that were gas-phase deglycosylated, and thus, were detected
unmodified are printed in blue. Fragment y8 belongs to this series only if Thr-10 is the modification site.
Mammalian O-glycosylation
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of ETD-derived backbone cleavages. Interestingly, the colli-
sional activation of some radical C-terminal ETD fragments
led to C-C bond cleavages in some amino acid side chains
yielding two w ions (for nomenclature see (99)), a phenome-
non already reported for the differentiation of the isomeric
Ile/Leu pair (100). Otherwise, no additional peptide fragmen-
tation was detected, rather the glycosidic bonds were
cleaved. An almost complete oxonium ion series was de-
tected for this glycopeptide. In contrast to “normal” HCD, the
single unit oxonium ions are weaker, the fragments distin-
guishing between GlcNAc and GalNAc were not observed,
m/z 366 representing HexHexNAc is missing, but all the larger
sialylated fragments are present, even the intact tetrasaccha-
ride. Because the low mass range is also covered, and abun-
dant reducing end fragments are also present and the ions are
measured within a few ppm, this technique seems to offer
more information about the glycans than ion trap CID.
In summary, we have to point out that usually none of the
above mentioned techniques provide “full glycan, amino acid
sequence and modification site assignment” coverage. All our
examples were singly modified glycopeptides and EThcD de-
livered the best results. However, peptides bearing multiple,
different O-glycan structures depending on their amino acid
and glycan sequences, carbohydrate/peptide size ratio, and
charge density still may yield very limited information from all
aspects.
Data Interpretation—Search engines were developed for
the identification of unmodified, mostly tryptic peptides. Co-
valent modifications that are stable on MS/MS activation and
are specific for any given amino acid make the assignment of
such modifications, including site determination, relatively
straightforward.
However, in O-glycosylation analysis we must deal with a
wide variety of glycans, and also with their potential coexis-
tence within the same peptide. Thus, even single protein
characterization can turn into a very complicated process,
and high throughput glycopeptide analysis remains extraor-
dinarily challenging. Unless a specific enrichment strategy
was followed (and even such protocols may produce surpris-
ing results (6)), multiple glycan structures must be listed as
potential variable modifications. Thus, in a way, a protein and
a glycan database search must be performed simultaneously.
In addition, the peptides may be decorated with multiple,
sometimes different glycans. Furthermore, both peptide and
FIG. 6. ETD spectrum ofm/z 733.692(3), acquired in the linear ion trap of an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher
Scientific). AQGSQVLES(HexNAcHex)TPPPHVMR [682–698] of human ITIH2 protein (Uniprot ID: P19823) was identified from these data. In
order to identify the peptide modified, common O-glycan structures were listed as variable modifications in the database search. The identity
or the linkage of the glycans cannot be established from these data. The fragments were measured with low resolution, thus, the charge state
of the ions was “determined” from the potential matches. Asterisks indicate the products of hydrogen migration, i.e. z1 fragments. Although
Ser-4 easily could be excluded as the glycosylation site, the C-terminal fragment printed in red provided the decisive information for the
assignment of Ser-9 for that role, because it indicates that Thr-10 is unmodified. Some carbohydrate fragmentation was also detected: the loss
of 42 Da from the N-acetylhexosamine, and some terminal hexose loss, both from the charge-reduced precursor ion. The precursor ion is
labeled as “pr.” The **-labeled ion is the charge-reduced ion of a coeluting (2) component.
Mammalian O-glycosylation
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glycan fragmentation must be considered. Activation-de-
pendent peptide fragmentation scoring and the probability-
based evaluation of the reliability thereof has been estab-
lished for unmodified sequences. Glycopeptide glycan
fragmentation assignment is like an “add-on” feature. Glyco-
peptide fragmentation has not been studied and evaluated yet
extensively, especially for O-glycosylation. We simply did not
have sufficiently large data sets available. What also compli-
cates the matter, that search strategies have been developed
to handle data from a single activation method. However, as
discussed earlier, for glycopeptide characterization it would
be better to use the information delivered by the different
MS/MS strategies combined, sometimes adding retention
time information and mass measurement data to the “mix-
ture.” Thus, we would need other “mining tools,” not only
humans, combining all these data. For the lack of better
solutions, there are studies, even of high throughput nature,
where data interpretation was/is performed from combined
MS/MS data, mostly manually (93–95). At the same time,
there are two search engines that are regularly used for O-
glycopeptide identification from ETD or HCD data, and these
are Byonic (101) and Protein Prospector (97, 102). Byonic is a
commercial product, whereas Protein Prospector is available
freely on the web and can also be downloaded and installed
in-house. These search engines display a comparable per-
formance and very similar shortcomings. Because Ser and
Thr residues are frequently located in clusters, even ETD
spectra may not reveal which amino acid bears the glycan.
Protein Prospector features a built-in site assignment evalu-
ation score, SLIP (site localization in peptide) score (103), and
it either will identify the glycosite confidently, or list the po-
tential modification sites whenever there is not sufficient in-
formation for site determination. As for HCD data the glycan
modification should be specified as “neutral loss” for Protein
Prospector (because of the preferential elimination of the
glycan on HCD activation, see MS/MS behavior section).
Byonic does not require such “special treatment,” and it la-
bels not only peptide fragments but also glycan oxonium ions
as well as some of the sugar losses. Unfortunately, it also will
“identify” a modification site even when there is no supportive
evidence in the spectrum that is usually the case. In addition,
characterizing peptides modified by multiple different O-gly-
cans has not been reliably solved yet, although both search
engines permit specifying such search parameters. For exam-
ple, a mass addition of 1312 Da may indicate the presence of
two GalGalNAc structures and two sialic acids. However, this
FIG. 7. EThcD spectrum of m/z 624.950(3), acquired on a Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher
Scientific) (at NCE  15%). The modified sequence was identified from these data as AVAVTLQSH [342–350] of human YIPF3 protein
(Uniprot ID: Q9GZM5). The glycan is most likely the disialo mucin-type core-1 structure, one of the glycans listed as potential variable
modifications of Ser and Thr residues. Extensive HexNAc fragmentation was not observed, thus, the GalNAc’s identity cannot be established
unambiguously from these data. In the reducing end fragment ion Y2SA, the sialic acid could be linked either to the GalNAc or the Gal. The
modification site was identified as Thr-5, fragments printed in red are unique to this positional variant. No fragment ions indicated modification
on the Ser residue. The precursor ion and its charge-reduced versions are labeled as “pr.”
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composition may correspond to a single hexasaccharide, or
two monosialo-structures, where the sialic acids might be
bond to either the Gal or the core GalNAc, or we may have a
combination of a disialo tetrasaccharide and an “uncapped”
disaccharide structure. EThcD may address some of these is-
sues, because it may contain sufficient information for glycan
size determination, peptide identification as well as site assign-
ment. However, to use reliably all the information included in the
spectra requires significant software development.
The data interpretation is not finished when the search
engine delivers a list of the identified glycopeptides, however
high the confidence level may be. As discussed earlier, certain
rules apply, such as where O-glycosylation is performed, what
kind of glycans can be deposited on the amino acid side
chains etc. Thus, we must consider the cellular localization of
the proteins on our list as well as their topology. Finding
extracellular glycosylation on—predicted to be—cytosolic
domains may overwrite topology predictions (6). Similarly,
allegedly cytosolic and nuclear proteins detected with extra-
cellular glycan structures might have been missassigned
or may have a secreted isoform. In addition, with the ever-
improving analytical tools one may discover novel, unex-
pected glycan structures or modification sites. For example,
mucin-type glycosylation has been reported for Tyr (30, 31)
and GlcNAcylation of Cys has been observed (104). HLA
peptides have been discovered featuring elongated GlcNAc
residues (105, 106). These neoantigens may serve as targets
for immunotherapy.
O-Glycosylation Studies
Single Protein Analysis—The analysis of isolated proteins
led to the discovery and characterization of the different type
of O-glycans. In the not so distant past proteases of different
specificity, glycosidases, and even Edman degradation had to
be used for such jobs. For example, the glycosylation of
human casein was studied using such methods in 1980 (107).
A decade later mass spectrometry was introduced into the
protein analytical repertoire and it holds a unique position
there ever since. All classes of O-glycosylation have been
described in single protein analysis using mass spectrometry.
(For references see: O-fucosylation (3, 4, 14, 19, 109); O-
glucosylation (15, 18, 19); mucin-type glycosylation (30, 71,
109–114); O-mannosylation (60, 62, 66)). Some proteins fea-
ture multiple types of O-glycosylation, such as Coagulation
Factor VII (115), Notch 1 (116), or dystroglycan (83). Single
protein analysis is still the best approach for the comprehen-
sive characterization of PTMs.
Recombinant Proteins—Presently, the majority of approved
biopharmaceuticals are glycoproteins. These represent a spe-
cific case of single protein characterization. As the physico-
chemical, pharmacokinetic, and immunologic properties of
these proteins may be altered by glycosylation changes, in-
depth glycoprofiling of these proteins is essential. To display
glycan pattern similar to that of human, these proteins are
usually expressed in eukaryotic cell lines such as Chinese
hamster ovary (CHO), myeloma (NS0), or hybridoma (SP2/0).
However, depending on the culture medium and the physio-
logical status of the host cells, the glycosylation pattern of
these proteins may vary batch-to-batch. Although therapeutic
efficacy, immunogenicity, and circulation half-life have clearly
been linked to N-glycosylation (117–120), the role of O-gly-
cosylation is less explored. Possible function of O-glycans
may be masking antigenic sites of the proteins as evidenced
by elevated antigenecity of O-glycosylation deficient human
recombinant granulocyte stimulating factor (121). Among
several glycan-related issues linked to N-glycosylation,
sialic acid O-acetylation, and the presence of the nonhuman
NeuGc may have implications toward O-linked structures as
well. The presence of these sialic acid variants have been
demonstrated on O-linked structures in wild-type samples
(1, 34).
The largest and best-selling therapeutic proteins are re-
combinant immunoglobulins (mAbs) applied widely for cancer
and autoimmune diseases. Proper N-glycosylation of IgGs is
indispensable for proper Fc-effector functions and serum
half-life. On the other hand, O-glycosylation has not been
observed on the most abundant IgG subclass, IgG1, although
O-glycosylation of the less abundant IgG2 and IgG3 sub-
classes has been reported (122, 123). Therefore, presently
there are no O-glycosylation issues related to this class of
biologics.
However, there are important biologics O-glycosylated.
Erythropoietin (EPO) is used for prevention of anemia in can-
cer patients and restoration of hemoglobin level in patients
with renal failure. Site-specific N- and O-glycosylation of this
30 kDa protein have been extensively studied (1, 124–128).
The human chorionic gonadotrophin, used for over 30 years
for treating female infertility, is a 26 kDa glycoprotein with 4 N-
and 4 O-glycosylation sites. In a recent study, ten different
samples from urinary- and recombinant hCGs were analyzed
and compared in a site-specific and quantitative manner
(129).
Therapeutic fusion proteins which are created from different
proteins using recombinant DNA technology may also belong
here. An example is Etanercept, a TNF inhibitor used for
treatment of rheumatoid arthritis. The linker region of this
protein is heavily O-glycosylated, 12 Ser/Thr residues have
been shown to be modified with neutral, mono- and disialy-
lated core-1 type structures (73).
High Throughput Data—Extracellular O-glycosylation data
acquired from complex samples are rather limited. The dy-
namic range of protein concentration is overwhelming in
body fluids or tissue samples—for example, concentration of
individual proteins spans 11 orders of magnitude in human
plasma (130), and the vast majority of these proteins are not-
or just N-glycosylated. To characterize O-glycosylation in
complex samples, some enrichment is essential. Basically,
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three enrichment strategies have been applied for this pur-
pose: (i) hydrophilic interaction liquid chromatography
(HILIC), (ii) periodate oxidation-hydrazide capture, and (iii) lec-
tin affinity chromatography.
HILIC is suitable for the enrichment of glycopeptides with
relatively high glycan/peptide ratio including N-glycopeptides
and multiply modified O-glycopeptides. Until now few O-
glycopeptides were characterized form such mixtures (131).
However, some O-glycosylated short peptide sequences,
such as those generated by aspecific/broad specificity pro-
teases may be isolated separately from N-glycopeptides as
demonstrated by a human plasma study incubating the sam-
ples with Proteinase K before the chromatography (95).
Though we would like to point out that automated interpreta-
tion of short peptide sequences generated by aspecific/broad
specificity proteases is usually quite unreliable.
The hydrazide capture and release approach exploits that
vicinal cis diols can be easily and selectively oxidized using
periodate and the resulting aldehydes can be isolated on
immobilized hydrazide functionalities. This method has been
developed for N-glycoprotein isolation (132) and further opti-
mized for enrichment of sialic acid containing glycoproteins
(133). The unmodified part of the protein is removed by tryptic
digestion followed by mild acidic release of the glycopeptides.
The glycosidic bond linking the terminal sialic acid and the
penultimate saccharide unit is hydrolyzed during this process,
information on the original intact glycan structure is therefore
lost. Similarly, to HILIC, both N- and O-glycosylated mole-
cules are isolated by this method. Peptides and proteins with
N-terminal Ser and Thr are also readily oxidized by periodate
(134), therefore this method is more suitable for protein-level
enrichment. The hydrazide capture-and release method has
been used for studying O-glycosylation in human urine (93)
and cerebrospinal fluid (94).
Finally, there are several lectins affording O-glycopeptide
enrichment. Jacalin, a plant lectin from Artocarpus integrifolia
shows preference toward Gal1,3GalNAc with unsubstituted
GalNAc C6-OH (135), therefore it is an attractive option for
samples such as human plasma/serum where mucin core-1
type O-glycosylation is dominant (136) keeping in mind that
the disialylated mucin core-1 structure that comprises some
20% of human plasma O-glycans (29) cannot be captured by
this lectin. Glycopeptides displaying core-2 O-glycans will
not be isolated either as the GlcNAc moiety is in 1,6 linkage
with the core GalNAc. Peanut agglutinin also binds the
Gal1,3GalNAc structure, but sialylation inhibits the binding
(137). Vicia villosa and soybean agglutinin show preference
toward GalNAc enabling enrichment of O-glycosylated pro-
teins or peptides from samples where elongation of mucin-
type O-glycosylation is inhibited (see Simple Cell technology
below). Finally, broad-specificity lectins such as wheat germ
agglutinin (138) can also be exploited for O-glycopeptide en-
richment. Although lectins show varying affinity toward their
preferred substrates, high nonspecific background is very
typical. This feature may partly be attributed to agarose fre-
quently used as solid support for lectin affinity chromatogra-
phy. Immobilization of lectins on other supports withstanding
more stringent washing conditions such as POROS (139) may
improve this situation.
Numerous O-glycosylation studies rely on lectin affinity iso-
lation. Jacalin has been used for O-glycosylation character-
ization of fetal calf serum (25, 92), human plasma (140) and
serum (79). Peanut agglutinin has been used for characteriza-
tion of protein O-glycosylation of human plasma, platelets and
endothelial cells (26) yielding the largest data set for protein
O-glycosylation to date. Wheat germ agglutinin has been
used in studies reporting O-glycosylation of the mouse syn-
aptosome (6) and liver (74), and this lectin also proved to be
useful for characterization of human serum O-glycosylation
(79, 80).
Interestingly, although HILIC, sialic-acid-based isolation as
well as affinity chromatography with wheat germ agglutinin
are suitable for the enrichment of some core mannosyl and
fucosyl structures, only a few such glycopeptides have been
identified in high-throughput studies (6). Thus, we must as-
sume that the occurrence of these modifications is much
lower than that of the mucin-type structures, and more tar-
geted enrichment strategies have to be developed in order to
find the differently O-glycosylated proteins.
SimpleCell Technology—Although the above examples
represented the analysis of wild-type samples, the most re-
markable breakthrough in O-glycosylation analysis has been
delivered by the Clausen-group introducing an innovative new
approach, SimpleCell technology. First, mucin-type O-glyco-
sylation has been extensively studied on genetically engi-
neered cell lines, where O-glycan extension is blocked (31,
141–143). This approach has been extended to probe the
specificity of different GalNAc-transferases (144, 145). The
latter studies revealed that there is significant redundancy in
the O-GalNAc transferase system, and most of the sites
are “covered” by multiple enzymes. However, the different
GalNAc transferases have specific substrate subsets that are
linked to distinct cellular processes. This suggests that some
GalNAc transferases may regulate these processes through
their specific substrate proteins. The technology was also
applied successfully to an entirely different glycosylation
pathway, O-mannosylation (59). Although very impressive re-
sults were gathered, the method suffers from certain short-
comings. The first results were gained from cancer cell lines.
Because it is believed that in cancer the equilibrium between
core glycosylation and elongation is broken (24), one would
expect a higher degree of glycosylation in such samples than
in healthy tissues, although we do not have any proof of that
(31). However, the authors themselves pointed out that higher
density glycosylation may result from the prevention of elon-
gation (141, 146). They also suggested that the increased
glycan density may adversely affect the proteolytic digestion
as well as mass spectrometry detection and MS/MS-based
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identification. On the other hand, in a recent study, King et al.
reported that there were no substantial differences between
site distribution and localization in glycoengineered immortal-
ized cell lines and in native samples (26). Distinguishing the
two N-acetylhexosamines used by human cells also repre-
sents a challenge for glycopeptides with truncated glycan
structures. Luckily, it has been reported that GalNAc and
GlcNAc produce a characteristic fragmentation pattern in
beam-type collisional activation (89). However, the reliability
of such assignments has not been tested on a large enough
data set yet. Obviously, the biggest issue with SimpleCell
technology is the loss of information on structural diversity.
Still, this is a very powerful tool, and there are numerous
promising projects where this technique will deliver signifi-
cant new knowledge, and will point us to the right direction.
Biological Significance
Cataloguing all proteins expressed within a given cell type
is not a straightforward task even in a qualitative manner,
despite the numerous claims of “comprehensive” character-
ization of different proteomes. Compiling the information
about O-glycosylation is on its way. Characterizing protein
populations, i.e. deciphering which modifications coexist has
just started for glycoproteins (71). Intact protein fractionation
and mass spectrometry seem to work better for N-glycopro-
teins (147), but the newest results are very promising for more
complex species as well (2). Elucidating the biological role of
these modifications, and how the macro- and microheteroge-
neity modulate these functions is another important question.
We listed some observations about the potential or proven
function of these PTMs above while describing the different
classes of O-glycosylation.
In addition, we want to point out that there are some excit-
ing possibilities for an “interplay” among different extracellular
post-translational modifications of Ser/Thr/Tyr residues. It is
widely accepted that intracellular GlcNAcylation of Ser/Thr
residues and the phosphorylation of the same sites or posi-
tions nearby may represent a regulatory switch (148). We
speculated that such interactions may not be restricted to the
intracellular space. Thus, we performed a preliminary investi-
gation how frequently these modifications occur on the same
residue or in close proximity (within 5 amino acids). We inves-
tigated glycoproteins identified in the first SimpleCell study
(31), and considered glycosylation sites reported then or later
by the same group. Most of these data are listed on Phos-
phoSitePlus, where we also found information about the
phosphorylation sites. In the Steentoft paper (31)350 O-gly-
cosylation sites in 122 proteins were reported. We found that
43 proteins featured 142 “overlapping” phosphorylation and
glycosylation sites. In most cases (113 instances) the very
same residues were assigned as modification sites in both
processes (supplemental Table S1). Similarly to the intercel-
lular GlcNAc/phosphorylation interplay (139), the degree of
overlapping may not be statistically significant in general, a
conclusion also reported along with the largest mucin-type
glycosylation data set (26). However, we believe for certain
proteins a strong correlation among these modifications may
exist, similarly to intracellular regulative processes (148). For
example, it has been reported that the secretion level of
FGF23 is controlled by a delicate balance between phos-
phorylation of Ser-180 and mucin-type glycosylation of Thr-
178 (149); and glycosylation defect in osteopontin led to in-
creased phosphorylation (41).
Site-specific glycan heterogeneity may represent a unique
kind of PTM-interplay. We need more information even to
guess the biological significance for displaying mucin-type
glycosylation versus mannosylation on the same site (6), or
glucosylation and fucosylation in close proximity (19); or for
altering the mucin-type core during membrane protein recy-
cling (78).
CONCLUSIONS
The glycosylation of isolated proteins, especially recombi-
nant biologicals have been studied for decades using a wide
variety of analytical tools, including mass spectrometry. The
analysis of intact proteins, the novel activation methods, ETD
and EThcD have been quickly introduced into the analytical
“tool set,” and made single protein characterization more
comprehensive, more successful. At the same time, high
throughput site-specific characterization of O-glycosylation
is still the exception not the norm, although there has been
significant progress in the large-scale analysis of protein O-
glycosylation in the last decade. Several enrichment methods
facilitating effective glycopeptide isolation have been devel-
oped. High sensitivity and high mass accuracy mass spec-
trometers equipped with ETD enable site-specific character-
ization of O-glycosylation. Bioinformatic tools for reliable
automated data interpretation are under progressive develop-
ment. Presently, integrative interpretation of MS/MS data ac-
quired with multiple fragmentation techniques is lacking, al-
though this approach would certainly lead to faster and more
reliable glycopeptide identifications. Thus, careful, critical in-
spection/evaluation of the automated assignments is still
highly recommended.
The vast majority of O-glycosylation data, both for single
protein- and large-scale analysis, was acquired on mucin type
O-glycosylation. The only other type of O-glycosylation tar-
geted by large-scale studies is O-mannosylation. Although
the Simple Cell technology yielded many mannosylation sites,
the only other large-scale study revealed a single O-manno-
sylated protein (the same study also reported an O-fucosy-
lated protein) (6). Single-protein studies have provided addi-
tional information on protein O-mannosylation, fucosylation
and glucosylation.
The largest mucin-type O-glycopeptide data set published
to date (26) identified over 1000 O-glycosylation sites in650
glycoproteins. Based on this amount of data we may start to
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speculate about potential novel functions of protein O-glyco-
sylation, as the authors indeed tried to identify shared features
and made certain predictions. As other studies will deliver
large scale O-glycosylation data from different sources, new
hypotheses will emerge and this process eventually will lead
to better understanding of the biological role(s) of O-glycosy-
lation—but there is a long way to go.
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